Interferon alpha 5(Biotecnol Ltd.)(Interferon alpha 5(Biotecnol Ltd.))

概要

基本信息

药物类型

干扰素

别名-

靶点

IFNAR

作用机制

IFNAR激动剂(干扰素α/β受体复合体激动剂)、免疫刺激剂

治疗领域

感染

在研适应症-

非在研适应症

感染

原研机构

Biotecnol Ltd.初创企业

在研机构-

非在研机构

Biotecnol Ltd.初创企业

最高研发阶段终止临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 Interferon alpha 5(Biotecnol Ltd.) 相关的临床结果

登录后查看更多信息

100 项与 Interferon alpha 5(Biotecnol Ltd.) 相关的转化医学

登录后查看更多信息

100 项与 Interferon alpha 5(Biotecnol Ltd.) 相关的专利（医药）

登录后查看更多信息

1

项与 Interferon alpha 5(Biotecnol Ltd.) 相关的文献（医药）

2011-10-10·Journal of Clinical Oncology

European Treatment and Outcome Study (EUTOS) Score for Chronic Myeloid Leukemia Still Requires More Confirmation

Letter

作者: Ibrahim, Amr R. ; Marin, David ; Goldman, John M.

TO THEEDITOR: In 1984, Sokal et al 1 developed a scoring system to predict the outcome of patients with chronic myeloid leukemia (CML). The scoring system rapidly gained popularity and has remained until now the most widely accepted method for assessing prognosisforpatientswithCML.AlthoughtheSokalscorewasdeveloped for patients with nonblastic disease who were treated with hydroxyureaorbusulfan,italsoprovedusefulforpredictingthesurvival of patients treated with interferon 2 and can predict the outcome for patients treated with imatinib. 3,4 Interestingly, it also predicts the outcome for patients who receive imatinib after experiencing treatment failure with interferon 5 and for patients who receive secondgeneration tyrosine kinase inhibitors after experiencing treatment failurewithimatinib. 6 TheconsistentvalueoftheSokalscoringsystem

100 项与 Interferon alpha 5(Biotecnol Ltd.) 相关的药物交易

登录后查看更多信息